Due to the link between obesity, insulin resistance and cancer, several FDA-approved antidiabetic therapies such as insulin sensitizers (thiazolidinediones), insulin secretagogues (sulfonylureas) and biguanides, which have been associated with the decrease in cancer incidence, are being investigated as anti-cancer therapies [5,6,7]. The gene discussed is INS; the disease is Obesity.